Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Glaxosmith (GLAXOSM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Glaxosmith historical data, for real-time data please try another search
17.70 +0.00    +0.00%
19/01 - Closed. Currency in NGN ( Disclaimer )
Type:  Equity
Market:  Nigeria
ISIN:  NGGLAXOSMTH8 
  • Volume: 0
  • Bid/Ask: 17.10 / 17.70
  • Day's Range: 17.00 - 17.00
Glaxosmith 17.70 +0.00 +0.00%

GLAXOSM Income Statement

 
Featured here, the Income Statement (earnings report) for Glaxosmith, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2023
30/09
2023
30/06
2023
31/03
2022
31/12
Total Revenue 3141.64 3731.8 4019.08 4956.84
Revenue 3141.64 3731.8 4019.08 4956.84
Other Revenue, Total - - - -
Cost of Revenue, Total 2462.62 2417.61 2540.62 3198.84
Gross Profit 679.02 1314.19 1478.46 1758
Total Operating Expenses 5062.61 3622.16 3859.88 4685.37
Selling/General/Admin. Expenses, Total 2600 1204.54 1319.26 1486.53
Research & Development - - - -
Depreciation / Amortization - 44.45 - 12.98
Interest Expense (Income) - Net Operating - - - -
Unusual Expense (Income) - - - -
Other Operating Expenses, Total - - - -
Operating Income -1920.98 109.64 159.19 271.47
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - 3.59 -16.44
Other, Net -2139.4 -164.1 -74.59 -236.96
Net Income Before Taxes 218.43 273.75 230.18 524.87
Provision for Income Taxes 110.06 89.2 75.01 237.27
Net Income After Taxes 108.36 184.55 155.17 287.6
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 108.36 184.55 155.17 287.6
Total Extraordinary Items - - - -
Net Income 108.36 184.55 155.17 287.6
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 108.36 184.55 155.17 287.6
Dilution Adjustment - - - -5.19
Diluted Net Income 108.36 184.55 155.17 292.8
Diluted Weighted Average Shares 1204.04 1230.34 1195.88 1158.38
Diluted EPS Excluding Extraordinary Items 0.09 0.15 0.13 0.248
DPS - Common Stock Primary Issue - - - 0.55
Diluted Normalized EPS 0.113 0.139 0.118 0.324
* In Millions of NGN (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GLAXOSM Comments

Write your thoughts about Glaxosmith
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Emmanuel Ohida
Emmanuel Ohida Apr 03, 2020 6:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Corona-virus is having a positive impact on the stock price. this can be attributed to anticipated increase in sale  due to of course increasing demand for  health product. Will the momentum be sustained?
Ufo Ufo
Ufo Ufo Apr 03, 2020 6:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Never paid attention to stocks in the Pharm sector until now. It's interesting to watch their performance on the floor. Your assertion makes sense. I'd also like to add CBN's recent support could have be playing a role here.
Toba Obiwale
Toba Obiwale Apr 03, 2020 6:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Despite the rise as at now, is it BUY OR NOT #GlaxoSmithKline
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email